Kura Oncology Stock (NASDAQ:KURA)
Previous Close
$16.88
52W Range
$8.17 - $24.17
50D Avg
$19.04
200D Avg
$20.12
Market Cap
$1.36B
Avg Vol (3M)
$531.32K
Beta
0.83
Div Yield
-
KURA Company Profile
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
KURA Performance
Peer Comparison
Ticker | Company |
---|---|
GRCL | Gracell Biotechnologies Inc. |
ZNTL | Zentalis Pharmaceuticals, Inc. |
KALV | KalVista Pharmaceuticals, Inc. |
KNSA | Kiniksa Pharmaceuticals, Ltd. |
VRDN | Viridian Therapeutics, Inc. |
MRUS | Merus N.V. |
LRMR | Larimar Therapeutics, Inc. |
DAWN | Day One Biopharmaceuticals, Inc. |
ERAS | Erasca, Inc. |
CERE | Cerevel Therapeutics Holdings, Inc. |
COGT | Cogent Biosciences, Inc. |
REPL | Replimune Group, Inc. |
SNDX | Syndax Pharmaceuticals, Inc. |
INZY | Inozyme Pharma, Inc. |
CRNX | Crinetics Pharmaceuticals, Inc. |
GLUE | Monte Rosa Therapeutics, Inc. |
DSGN | Design Therapeutics, Inc. |
PTGX | Protagonist Therapeutics, Inc. |